First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience

Randomized phase III trials have shown significant improvement of survival 1, 2, and 3 years after implantation of 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) wafers for patients with newly diagnosed malignant glioma. But these studies and subsequent non-phase III studies have also shown risks asso...

Descripción completa

Detalles Bibliográficos
Autores principales: Bock, Hans Christoph, Puchner, Maximilian Josef Anton, Lohmann, Frauke, Schütze, Michael, Koll, Simone, Ketter, Ralf, Buchalla, Ruediger, Rainov, Nikolai, Kantelhardt, Sven R., Rohde, Veit, Giese, Alf
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936684/
https://www.ncbi.nlm.nih.gov/pubmed/20706757
http://dx.doi.org/10.1007/s10143-010-0280-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936684/
https://www.ncbi.nlm.nih.gov/pubmed/20706757
http://dx.doi.org/10.1007/s10143-010-0280-7

Ejemplares similares